Sanofi Genzyme, a global business unit of Sanofi, has secured a $37.6m contract from the Biomedical Advanced Research and Development Authority (BARDA), for the supply and manage inventory for Leukine.

Leukine is a treatment for acute radiation syndrome, an illness that can damage organs including the bone marrow, gastrointestinal tract and lungs.

It can also cause neutropenia, an abnormally low level of white blood cells that fight infection called neutrophils.

"We are pleased to be able to partner with BARDA to support public health."

Sanofi Genzyme Rare Diseases global head Richard Peters said: “According to the centres for disease control and prevention, the cause of death in most cases of acute radiation syndrome is the destruction of the person's bone marrow.

“We are pleased to be able to partner with BARDA to support public health.”

In 2013, Sanofi secured a $36.5m contract for late stage development and procurement of Leukine.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company has conducted tests regarding the potential use of Leukine in patients acutely exposed to myelosuppressive doses of radiation.

Sanofi Genzyme is planning to submit a supplemental biologics licence application (sBLA) to the US Food and Drug Administration in 2017.

BARDA develops vaccines, drugs, therapies, and diagnostic tools for public-health medical emergencies.